Observational studyBritish journal of clinical pharmacology2025
A multidisciplinary meeting for generating a personalized pharmaceutical plan for older adults at hospital discharge: the IATROPREV study.
Observational study in British journal of clinical pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Medication review in older adults at hospital discharge: an analysis of data from the IATROPREV study.European geriatric medicine · 2026Observational
- A multidisciplinary meeting for generating a personalized pharmaceutical plan for older adults at hospital discharge: the IATROPREV study.British journal of clinical pharmacology · 2025Observational
- Balance and Gait Disorders in the Aged Population. Causes, Assessment and Management: A Literature Review.Clinical interventions in aging · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe French government's IATROPREV program has been designed to assess the effectiveness and safety of medications prescribed to older adults discharged from acute geriatric units. IATROPREV includes the implementation of a personalized pharmaceutical plan validated at a multidisciplinary meeting attended by the patient's geriatrician, family physician, community pharmacist and hospital pharmacist. We hypothesized that a multidisciplinary meeting on discharge from hospital will enable the recommendations to be largely followed up.
methodsA prospective, observational, multicentre study was conducted to analyse the personalized pharmaceutical plan and follow-up at 45 and 90 days for patients discharged from an acute geriatric unit between February 2021 and August 2023.
resultsOf 708 eligible patients, 380 (54%) were included. The main reason for non-inclusion was the family physician's refusal to participate. A total of 5977 recommendations (i.e., an average of 15 per patient) were issued during the multidisciplinary meeting. Seventy percent of these recommendations concerned medication adjustments. The remaining recommendations were related to clinical and laboratory follow-up, the management of home care, and vaccination updates. Follow-up data at 90 days were available for 295 (78%) of the 380 patients. At 90 days, the recommendation implementation rate was 83% (4178 out of 5977) overall, 86% for medication adjustments, 79% for patient monitoring, 87% for home care management and 56% for vaccinations.
conclusionsIATROPREV is designed for patients with major therapeutic complexity. It enables a significant number of treatment optimization recommendations to be implemented within 90 days, thanks in particular to the multidisciplinary meeting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.